• Cannabidiol approved by Scottish Medicines Consortium

    News

    Cannabidiol approved by Scottish Medicines Consortium

    GW Pharmaceuticals, specialising in discovery and development of regulatory approved cannabis-based medicines, operating as a subsidiary of Dublin-based Jazz pharmaceuticals, has received confirmation that its Epidyolex® (cannabidiol) has been accepted by the Scottish Medicines Consortium (SMC) for use within NHS Scotland for adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC), for patients two years of age and older.

    Scotland is the second UK nation to make Epidyolex available for routine reimbursement for all three conditions for which it is licensed, following the All Wales Medicines Strategy Group’s (AWMSG’s) recommendation in December 2021. This  therapy and its applications was also approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) in August 2021.

    “This is an important decision by the SMC and an exciting development for patients, their families and clinicians in Scotland, giving those suffering from this difficult to treat condition access to a new treatment option,” said Chris Tovey, executive vice president, chief operating officer and managing director, Europe & International at Jazz Pharmaceuticals. “The decision to reimburse Epidyolex demonstrates that, if provided with high-quality evidence, health authorities can provide access to rigorously-tested cannabis-based medicines to patients who could benefit from them.”

    Louise Fish, Chief Executive, Tuberous Sclerosis Association said: “The decision to reimburse this medicine for TSC is very welcome news for people living with TSC and their families. TSC is often a difficult to manage condition, causing epilepsy in eight out of ten people living with the condition, and up to 60% of people with TSC-related epilepsy do not respond to standard anti-seizure medication. New treatment options for TSC are desperately needed, and we are delighted that this medicine will now be available on the NHS for eligible patients in Scotland.”

    More information online


    Digital Edition

    Lab Asia 32.2 April

    April 2025

    Chromatography Articles - Effects of small deviations in flow rate on GPC/SEC results Mass Spectrometry & Spectroscopy Articles - Waiting for the present to catch up to the future: A bette...

    View all digital editions

    Events

    Medtec Japan 2025

    Apr 09 2025 Tokyo, Japan

    FORUMESURE

    Apr 22 2025 Hammamet, Tunisia

    Korea Lab 2025

    Apr 22 2025 Kintex, South Korea

    Analytica Anacon India & IndiaLabExpo

    Apr 23 2025 Mumbai, India

    Analitika Expo 2024

    Apr 23 2025 Moscow, Russia

    View all events

    Great Job...
    The latest issue will be with you shortly
    Sign up to Labmate for FREE.
    Register and get the eBulletin, a Monthly email packed with the latest Laboratory products, news and services. Join us and get the latest Laboratory information first.